Literature DB >> 29510390

International Consensus Statement on Screening, Diagnosis and Treatment of Substance Use Disorder Patients with Comorbid Attention Deficit/Hyperactivity Disorder.

Cleo L Crunelle1,2, Wim van den Brink3, Franz Moggi4, Maija Konstenius5, Johan Franck5, Frances R Levin6, Geurt van de Glind7, Zsolt Demetrovics8, Corné Coetzee9, Mathias Luderer10, Arnt Schellekens11, Frieda Matthys1.   

Abstract

Adult attention deficit/hyperactivity disorder (ADHD) often co-occurs with substance use disorders (SUD) and is associated with early onset and more severe development of SUD and with reduced treatment effectiveness. Screening tools allow for a good recognition of possible ADHD in adults with SUD and should be used routinely, followed by an ADHD diagnostic process initiated as soon as possible. Simultaneous and integrated treatment of ADHD and SUD, using a combination of pharmaco- and psychotherapy, is recommended. Long-acting methylphenidate, extended-release amphetamines, and atomoxetine with up-titration to higher dosages may be considered in patients unresponsive to standard doses. This paper includes evidence- and consensus-based recommendations developed to provide guidance in the screening, diagnosis and treatment of patients with ADHD-SUD comorbidity.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Attention deficit/hyperactivity disorder; Consensus; Diagnosis; Substance use disorders; Treatment

Mesh:

Substances:

Year:  2018        PMID: 29510390      PMCID: PMC5986068          DOI: 10.1159/000487767

Source DB:  PubMed          Journal:  Eur Addict Res        ISSN: 1022-6877            Impact factor:   3.015


  53 in total

1.  Psychiatric comorbidity in treatment-seeking substance use disorder patients with and without attention deficit hyperactivity disorder: results of the IASP study.

Authors:  Katelijne van Emmerik-van Oortmerssen; Geurt van de Glind; Maarten W J Koeter; Steve Allsop; Marc Auriacombe; Csaba Barta; Eli Torild H Bu; Yuliya Burren; Pieter-Jan Carpentier; Susan Carruthers; Miguel Casas; Zsolt Demetrovics; Geert Dom; Stephen V Faraone; Melina Fatseas; Johan Franck; Brian Johnson; Máté Kapitány-Fövény; Sharlene Kaye; Maija Konstenius; Frances R Levin; Franz Moggi; Merete Møller; J Antoni Ramos-Quiroga; Arild Schillinger; Arvid Skutle; Sofie Verspreet; Wim van den Brink; Robert A Schoevers
Journal:  Addiction       Date:  2013-11-20       Impact factor: 6.526

2.  Need for care and life satisfaction in adult substance use disorder patients with and without attention deficit hyperactivity disorder (ADHD) or autism spectrum disorder (ASD).

Authors:  Linda M Kronenberg; Peter J J Goossens; Derk M van Etten; Theo van Achterberg; Wim van den Brink
Journal:  Perspect Psychiatr Care       Date:  2014-01-10       Impact factor: 2.186

3.  Psychosis induced by the interaction between disulfiram and methylphenidate may be dose dependent.

Authors:  Lara Grau-López; Carlos Roncero; Maria C Navarro; Miquel Casas
Journal:  Subst Abus       Date:  2012       Impact factor: 3.716

4.  Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo.

Authors:  Frances R Levin; Suzette M Evans; Daniel J Brooks; Aparna S Kalbag; Fatima Garawi; Edward V Nunes
Journal:  Drug Alcohol Depend       Date:  2005-08-15       Impact factor: 4.492

5.  Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders.

Authors:  Timothy E Wilens; Lenard A Adler; Margaret D Weiss; David Michelson; Janet L Ramsey; Rodney J Moore; Didier Renard; Kathleen T Brady; Paula T Trzepacz; Leslie M Schuh; Lisa M Ahrbecker; Louise R Levine
Journal:  Drug Alcohol Depend       Date:  2008-04-09       Impact factor: 4.492

6.  Unrecognized attention-deficit/hyperactivity disorder in adults presenting with other psychiatric disorders.

Authors:  Russell A Barkley; Thomas E Brown
Journal:  CNS Spectr       Date:  2008-11       Impact factor: 3.790

7.  A randomized controlled trial of pemoline for attention-deficit/hyperactivity disorder in substance-abusing adolescents.

Authors:  Paula D Riggs; Shannon K Hall; Susan K Mikulich-Gilbertson; Michelle Lohman; Ashley Kayser
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2004-04       Impact factor: 8.829

8.  Validity of the Adult ADHD Self-Report Scale (ASRS) as a screener for adult ADHD in treatment seeking substance use disorder patients.

Authors:  Geurt van de Glind; Wim van den Brink; Maarten W J Koeter; Pieter-Jan Carpentier; Katelijne van Emmerik-van Oortmerssen; Sharlene Kaye; Arvid Skutle; Eli-Torild H Bu; Johan Franck; Maija Konstenius; Franz Moggi; Geert Dom; Sofie Verspreet; Zsolt Demetrovics; Máté Kapitány-Fövény; Melina Fatséas; Marc Auriacombe; Arild Schillinger; Andrea Seitz; Brian Johnson; Stephen V Faraone; J Antoni Ramos-Quiroga; Miguel Casas; Steve Allsop; Susan Carruthers; Csaba Barta; Robert A Schoevers; Frances R Levin
Journal:  Drug Alcohol Depend       Date:  2013-05-06       Impact factor: 4.492

9.  An epidemiological study of ADHD, substance use, and comorbid problems in incarcerated women in Sweden.

Authors:  Maija Konstenius; Henrik Larsson; Lena Lundholm; Bjorn Philips; Geurt van de Glind; Nitya Jayaram-Lindström; Johan Franck
Journal:  J Atten Disord       Date:  2012-07-13       Impact factor: 3.256

10.  Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: a 24-week randomized placebo-controlled trial.

Authors:  Maija Konstenius; Nitya Jayaram-Lindström; Joar Guterstam; Olof Beck; Björn Philips; Johan Franck
Journal:  Addiction       Date:  2013-12-01       Impact factor: 6.526

View more
  17 in total

Review 1.  The International Collaboration on ADHD and Substance Abuse (ICASA): Mission, Results, and Future Activities.

Authors:  Geurt Van de Glind; Christoffer Brynte; Arvid Skutle; Sharlene Kaye; Maija Konstenius; Frances Levin; Frieda Mathys; Zsolt Demetrovics; Franz Moggi; Josep Antoni Ramos-Quiroga; Arnt Schellekens; Cleo Crunelle; Geert Dom; Wim van den Brink; Johan Franck
Journal:  Eur Addict Res       Date:  2020-06-29       Impact factor: 3.015

2.  Often Overlooked and Ignored, but Do Not Underestimate Its Relevance: ADHD in Addiction - Addiction in ADHD.

Authors:  Arnt F A Schellekens; Wim van den Brink; Falk Kiefer; Anneke E Goudriaan
Journal:  Eur Addict Res       Date:  2020-07-02       Impact factor: 3.015

Review 3.  Risks and Benefits of Attention-Deficit/Hyperactivity Disorder Medication on Behavioral and Neuropsychiatric Outcomes: A Qualitative Review of Pharmacoepidemiology Studies Using Linked Prescription Databases.

Authors:  Zheng Chang; Laura Ghirardi; Patrick D Quinn; Philip Asherson; Brian M D'Onofrio; Henrik Larsson
Journal:  Biol Psychiatry       Date:  2019-04-17       Impact factor: 13.382

4.  Prescription Stimulant Use and Misuse: Implications for Responsible Prescribing Practices.

Authors:  Amelia M Arria; Robert L DuPont
Journal:  Am J Psychiatry       Date:  2018-08-01       Impact factor: 18.112

5.  [ADHD screening in alcohol dependent subjects : Psychometric characteristics of ADHD self-report scale and Wender Utah Rating Scale short form].

Authors:  Mathias Luderer; Nurcihan Kaplan-Wickel; Christian Sick; Agnes Richter; Iris Reinhard; Falk Kiefer; Tillmann Weber
Journal:  Nervenarzt       Date:  2019-11       Impact factor: 1.214

Review 6.  Clinically Significant Drug-Drug Interactions with Agents for Attention-Deficit/Hyperactivity Disorder.

Authors:  Georgios Schoretsanitis; Jose de Leon; Chin B Eap; John M Kane; Michael Paulzen
Journal:  CNS Drugs       Date:  2019-12       Impact factor: 5.749

Review 7.  [ADHD in adult patients with substance use disorders].

Authors:  Mathias Luderer; Falk Kiefer; Andreas Reif; Franz Moggi
Journal:  Nervenarzt       Date:  2019-09       Impact factor: 1.214

Review 8.  The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder.

Authors:  Stephen V Faraone; Tobias Banaschewski; David Coghill; Yi Zheng; Joseph Biederman; Mark A Bellgrove; Jeffrey H Newcorn; Martin Gignac; Nouf M Al Saud; Iris Manor; Luis Augusto Rohde; Li Yang; Samuele Cortese; Doron Almagor; Mark A Stein; Turki H Albatti; Haya F Aljoudi; Mohammed M J Alqahtani; Philip Asherson; Lukoye Atwoli; Sven Bölte; Jan K Buitelaar; Cleo L Crunelle; David Daley; Søren Dalsgaard; Manfred Döpfner; Stacey Espinet; Michael Fitzgerald; Barbara Franke; Manfred Gerlach; Jan Haavik; Catharina A Hartman; Cynthia M Hartung; Stephen P Hinshaw; Pieter J Hoekstra; Chris Hollis; Scott H Kollins; J J Sandra Kooij; Jonna Kuntsi; Henrik Larsson; Tingyu Li; Jing Liu; Eugene Merzon; Gregory Mattingly; Paulo Mattos; Suzanne McCarthy; Amori Yee Mikami; Brooke S G Molina; Joel T Nigg; Diane Purper-Ouakil; Olayinka O Omigbodun; Guilherme V Polanczyk; Yehuda Pollak; Alison S Poulton; Ravi Philip Rajkumar; Andrew Reding; Andreas Reif; Katya Rubia; Julia Rucklidge; Marcel Romanos; J Antoni Ramos-Quiroga; Arnt Schellekens; Anouk Scheres; Renata Schoeman; Julie B Schweitzer; Henal Shah; Mary V Solanto; Edmund Sonuga-Barke; César Soutullo; Hans-Christoph Steinhausen; James M Swanson; Anita Thapar; Gail Tripp; Geurt van de Glind; Wim van den Brink; Saskia Van der Oord; Andre Venter; Benedetto Vitiello; Susanne Walitza; Yufeng Wang
Journal:  Neurosci Biobehav Rev       Date:  2021-02-04       Impact factor: 9.052

9.  Investigating genetic correlation and causality between nicotine dependence and ADHD in a broader psychiatric context.

Authors:  Jacqueline M Vink; Jorien L Treur; Joëlle A Pasman; Arnt Schellekens
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2020-09-10       Impact factor: 3.358

10.  Adult attention-deficit/hyperactivity disorder symptoms, cognitive dysfunction and quality of life in high-dose use of benzodiazepine and Z-drug.

Authors:  Fabio Lugoboni; Stefano Tamburin; Angela Federico; Elisa Mantovani; Rebecca Casari; Anna Bertoldi
Journal:  J Neural Transm (Vienna)       Date:  2020-12-17       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.